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Androgen receptor (AR) is essential for the growth and progression
of prostate cancer in both hormone-sensitive and hormone-refrac-
tory disease. A DNA-binding polyamide that targets the consensus
androgen response element binds the prostate-specific antigen
(PSA) promoter androgen response element, inhibits androgen-
induced expression of PSA and several other AR-regulated genes in
cultured prostate cancer cells, and reduces AR occupancy at the PSA
promoter and enhancer. Down-regulation of PSA by this poly-
amide was comparable to that produced by the synthetic antian-
drogen bicalutamide (Casodex) at the same concentration. Ge-
nome-wide expression analysis reveals that a similar number of
transcripts are affected by treatment with the polyamide and with
bicalutamide. Direct inhibition of the AR-DNA interface by se-
quence-specific DNA binding small molecules could offer an alter-
native approach to antagonizing AR activity.
prostate cancer  bicalutamide  small molecule  transcription
The androgen receptor (AR) is a member of the ligand-activated nuclear receptor family of transcription factors (1).
Ligand binding to AR initiates release from the cytoplasm,
dimerization, binding to the androgen response elements (ARE)
of target genes, and gene activation through interaction with
coactivators and the general transcription machinery (2). Func-
tional AREs, consensus sequence 5-GGTACAnnnTGTTCT-3
(Fig. 1A) (3) can occur in proximal promoter sequences or in
enhancers located up to several thousand base pairs upstream or
downstream of the transcription start site.
The regulation of prostate-specific antigen (PSA) (KLK3)
expression by AR has been extensively studied as a model for
AR-mediated gene activation (4–7). Androgenic induction of
PSA is mediated by AR binding to the proximal promoter 170
bp from the transcription start site and to several low-affinity
AREs in an enhancer4,000 bp upstream (4–6). AREs in both
the promoter and enhancer are important for induction after
androgen stimulation. AR occupies both the promoter and
enhancer regions and recruits transcriptional coactivators in-
cluding p160 and p300, TATA-binding protein, mediator, and
RNA polymerase II to form the AR transcription complex (7, 8).
Chromatin-capture assays suggest that the PSA enhancer is
located near the promoter in this complex (8).
AR signaling regulates normal prostate development and
contributes to the progression of prostate cancer (9). Surgical or
drug therapies that act to limit circulating androgen levels or
directly antagonize ligand binding to AR initially slow prostate
cancer growth (10, 11). However, nearly all patients treated with
antiandrogen therapies will eventually develop hormone-
refractory disease (12). Dysregulation of AR activity, together
with activation of the PTEN/AKT pathway, is thought to con-
tribute to this transition (13). Up-regulation of AR mRNA was
found to occur in all transitions from hormone-sensitive to
hormone-refractory disease in a mouse tumor-xenograft model
of prostate cancer (14). Additionally, a transgenic mouse with a
mutated AR that inappropriately interacts with transcriptional
coregulators developed metastatic neoplastic disease (15). Mu-
tations in the AR ligand-binding domain can render antagonists
such as bicalutamide or flutamide ineffective or, in some models
of hormone-refractory disease, convert them to agonists (14, 16).
Given that genotropic AR activity is thought to be necessary
throughout prostate cancer progression, direct antagonism of
AR–DNA binding could inhibit androgen receptor activity in
hormone-refractory conditions where androgen antagonists that
target the ligand-binding pocket are ineffective (9).
DNA-binding polyamides represent one approach to inhibit-
ing protein–DNA interactions. Polyamides containing N-
methylimidazole (Im) andN-methylpyrrole (Py) comprise a class
of programmable DNA-binding ligands capable of binding to a
broad repertoire of DNA sequences with affinities and speci-
ficities comparable to those of natural DNA-binding proteins
(17, 18). Sequence specificity is programmed by side-by-side
pairings of the heterocyclic amino acids in the minor groove of
DNA: Im/Py distinguishes GC from CG; Py/Py binds both AT
and TA (19, 20). Previously, a hairpin polyamide targeted to the
hypoxia response element (HRE) inhibited hypoxia-induced
expression of several HIF-1-regulated genes, including VEGF, in
cultured cells (21, 22).
In this study, we have designed a cell-permeable polyamide to
target the sequence 5-WGWWCW-3, found in the consensus
ARE, with the goal of disrupting AR-mediated gene expression
(Fig. 1). We show that this polyamide binds the ARE found in
the PSA promoter, inhibits expression of PSA as well as 35%
of the transcripts that were induced by dihydrotestosterone
(DHT) in cultured prostate cancer cells, and reduces AR
occupancy at the PSA promoter and enhancer. Down-regulation
of PSA by this polyamide was comparable to the effects of the
synthetic antiandrogen bicalutamide (Casodex) at the same
concentration. A control polyamide targeted to a different
sequence had less effect.
Results
Binding Affinities of Polyamides to the ARE of the PSA Promoter. The
proximal PSA promoter contains the ARE 5-AGAACAG-
CAAGTGCT-3 (Fig. 2A). The DNA binding of polyamides 1
and 2 on this sequence was measured by quantitative DNase I
footprint titrations using a 5-32P-labeled PCR fragment of
pAR-PSA, which contains the PSA ARE. Polyamide 1 has a
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Ka  8.3  1.7  109 M1 for the ARE consensus half-site
5-AGAACA-3 (Fig. 2B). Binding of polyamide 2, which targets
the sequence 5-WGWCGW-3, to the ARE is not measurable
by these methods (Ka  1  107) (Fig. 2C). Minimal binding of
polyamide 1 is observed at the other half-site of the ARE:
5-AGTGCT-3, which is formally a single base pair mismatch
site for 1. However, 1 is observed to bind the sequence 5-
AGATCA-3 12 bp 5 to the ARE, which is an expected
binding site for this molecule.
Electrophoretic Mobility Shift Assay. The effects of polyamides 1
and 2 on the binding of factors present in the nuclear extract
isolated from DHT-stimulated LNCaP cells to the ARE site in
the PSA promoter was measured by an electrophoretic mobility
shift assay (Fig. 2D). Polyamide 1 inhibits binding to the 5-32P-
labeled duplex at concentrations as low as 10 nM. Polyamide 2
has minimal effect at the same concentrations.
Inhibition of Androgen-Inducted PSA Expression. Induction of PSA
mRNA by DHT in the presence of polyamides 1 and 2 and
bicalutamide in LNCaP cells was measured by quantitative
real-time RT-PCR. Bicalutamide and polyamide 1 inhibit the
expression of DHT-induced PSA in a dose-dependent manner
up to 70% at 10 M, as measured in this assay (Fig. 3A).
Polyamide 2 has a more modest effect. Secretion of PSA protein
after DHT stimulation of LNCaP cells in the presence of 1 and
2 was measured by ELISA (Fig. 3B). Supernatant concentrations
of PSA protein are reduced in cells pretreated with 1 as
compared with 2 or an untreated control. AR occupancy at the
PSA promoter and enhancer was assessed by chromatin immu-
noprecipitation (Fig. 3C). Chromatin immunoprecipitation as-
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Fig. 1. Targeting the ARE with DNA-binding polyamides. (A) Model of the
AR transcription complex. (B) Consensus ARE. (C) Structures and ball-and-stick
models of polyamides 1, designed to bind the consensus ARE, and 2, a 2-bp
mismatch. Imidazole andpyrrolemonomer units are representedbyfilled and
open circles, respectively. The isophthalic acid tail moiety is represented by an
hexagon.
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Fig. 2. Binding of 1 and 2 to the ARE in the PSA promoter. (A) Illustration of
pAR and partial sequence of the PSA promoter. (B) Quantitative DNase I
footprint titration experiments for polyamides 1 and 2 on the 5-end-labeled
PCR product of plasmid pAR-PSA: lane 1, intact DNA; lane 2, A reaction; lane
3, G reaction; lane 4, DNase I standard; lanes 5–15, 1 pM, 3 pM, 10 pM, 30 pM,
100 pM, 300 pM, 1 nM, 3 nM, 10 nM, 30 nM, 100 nM polyamide, respectively.
(C) Isotherm for 1 binding to the ARE half-site 5-AGAACA-3. Polyamide 1 has
a Ka 8.3 1.7 109 for this site. Polyamide 2 shows no measurable binding
in the footprinted region. (D) EMSA of DHT-stimulated LNCaP cell nuclear
extract (NE) binding to a 31-bp oligonucleotide duplex containing the PSA
promoter ARE in the presence of 1 and 2.
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says with anti-AR antibody treatment indicate decreased occu-
pancy of AR at the PSA promoter and enhancer in the presence
of 10 M 1. Polyamide 2 has minimal effect. Polyamides 1 and
2 display no obvious detrimental effects on cell growth over the
course of the experiment. AR mRNA is minimally affected by 1
[see supporting information (SI) Fig. 5].
Inhibition of Androgen-Induced FKBP5 Expression. Recent studies
have identified FKBP5 as one of the most strongly induced genes
in androgen-stimulated prostate cancer cells (23). Two func-
tional AREs with the sequences 5-AGCACATCGAGTTCA-3
and 5-AGAACAGGGTGTTCT-3 have been mapped to an
enhancer within the fifth intron (24). Polyamide 1 inhibits
DHT-induced expression of FKBP5 by 60% (Fig. 3D). Bica-
lutamide was more potent, however, inhibiting expression by
almost 95%. Polyamide 2 has minimal effect on FKBP5 expres-
sion. Chromatin immunoprecipitation assays indicate decreased
occupancy of AR at the FKBP5 intronic enhancer in the
presence of 10 M 1 (Fig. 3E), whereas polyamide 2 has no
measurable effect.
Global Effects on Androgen-Induced Gene Expression.Global effects
of polyamides 1 and 2 and bicalutamide on gene expression in
DHT-stimulated LNCaP cells were monitored with Affymetrix
(Santa Clara, CA) high-density Human Genome U133 Plus 2.0
arrays, which interrogate50,000 transcripts. As compared with
DHT-induced controls, polyamide 1 (10 M) affected the
expression of 1,053 transcripts by at least 2-fold (P 0.01) (Table
1), which represents less than 2% of interrogated transcripts. Of
this total, 706 were down-regulated. At the same threshold,
bicalutamide (10 M) affected the expression of 1,213 tran-
scripts, with 602 of these being down-regulated. Polyamide 2 (10
M) affected the expression of 379 transcripts, which represents
1% of interrogated transcripts. A divisive clustering analysis
over all interrogated transcripts suggests that the expression
profiles of cells treated with bicalutamide, 1, and 2 are largely
distinct (Fig. 4A). Analysis of transcripts affected by both
bicalutamide and 1 shows that 122 and 90 transcripts are
commonly down- and up-regulated, respectively, at least 2-fold
(P  0.01) (Fig. 4B). Of the 122 transcripts down-regulated by
both bicalutamide and 1, 117 are also observed to be induced by
DHT at the same thresholds. Of the 90 up-regulated transcripts,
59 are observed to be repressed by DHT.
The response of cultured prostate cancer cells to androgen has
been extensively studied (23, 25). We find that DHT induced the
expression of a set of 199 transcripts by at least 4-fold (P 0.01).
Of this set, 70 were also inhibited by polyamide 1 by at least
2-fold (P 0.01). For comparison, polyamide 2 inhibited 20, and
bicalutamide inhibited 186, of the 199 DHT-induced transcripts
with the same thresholds (Fig. 4C). DHT repressed the expres-
sion of a set of 88 transcripts by at least 4-fold (P 0.01). Of this
set, eight were also derepressed, as compared with DHT-treated
controls, by polyamide 1 by at least 2-fold (P  0.01). For
comparison, polyamide 2 derepressed 3, and bicalutamide de-
repressed 87, of the 88 transcripts repressed by DHT with the
same thresholds (Fig. 4C). A complete list of the DHT-induced
transcripts and those affected by 1 is provided in SI Tables 3 and
4. It is not known what proportions of these genes are direct
targets of AR. Table 2 displays the effects of each treatment on
the expression of a few selected genes that were observed to be
induced by DHT and are known to be targets of AR (26, 27).
Effects on the expression of KLK2 and TMPRSS2 were verified
by quantitative real-time RT-PCR (SI Fig. 5).
Discussion
Because numerous signaling pathways converge on a smaller
number of transcription factors to exert their effects on gene
expression, it has been proposed that transcription factors could
be among the most appropriate drug targets in oncology (28, 29).
This possibility has underscored the challenge to design small
molecules capable of selectively disrupting protein–protein in-
teractions between coactivators as well as protein–DNA inter-
actions between transcription factors and their target sites in
gene regulatory sequences.
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Fig. 3. Inhibition of DHT-induced PSA and FKBP5 expression by 1 and 2. (A)
Induction of PSA mRNA in the presence of 1 and 2 and bicalutamide, B,
measuredbyquantitative real-timePCR.1andbicalutamide inhibit expression
of PSA in a dose-dependent manner up to 70% at 10 M. 2 has a more
modest effect. (B) Secreted PSA protein measured by ELISA. (C) Chromatin
immunoprecipitation assays with anti-AR or mock antibody treatment ex-
pressed as fold-enrichment (specific/mock) of DNA sequences at the PSA
promoter and enhancer. AR occupancy at the PSA promoter and enhancer is
decreased in thepresenceof1 (10M)butnot2. (D) Inductionof FKBP5mRNA
in the presence of 1 and 2 and bicalutamide, B. (E) Chromatin immunopre-
cipitation assays with anti-AR at the FKBP5 fifth intron enhancer. Polyamide
concentrations are 10 M.
10420  www.pnas.orgcgidoi10.1073pnas.0704217104 Nickols and Dervan
Prostate cancer cells depend on stimulation by circulating
androgens that exert their effects through the AR signaling axis.
Hormone therapies that block AR activity by starving it of
androgens or inhibiting ligand binding are initially successful but
ultimately fail to control disease (12). This failure can occur
through up-regulation of AR, mutations in the ligand-binding
pocket, and ligand-independent activation from upstream sig-
naling proteins (13, 30, 31). It is thought, however, that intact
activity of AR signaling is necessary for disease progression (9).
Inhibition of the AR–DNA interaction by a sequence-specific
DNA-binding molecule could be expected to interfere with AR
signaling under both hormone-sensitive and hormone-refractory
conditions.
Polyamide 1 binds to a half-site of the ARE of the PSA
promoter with a subnanomolar Kd and inhibits expression of
35% of transcripts that are observed to be induced at least
4-fold by DHT in LNCaP cells. Down-regulation of PSA by this
polyamide is comparable to that produced by the synthetic
antiandrogen bicalutamide at the same concentration. Control
polyamide 2, which targets a different DNA sequence, 5-
WGWCGW-3, had significantly less effect on androgen-
induced gene expression. Expression of PSA (KLK3), KLK2,
TMPRSS2, and FKBP5, which are direct AR targets, were all
affected by 1. TMPRSS2 encodes a transmembrane protease and
can undergo a chromosomal deletion in which a member of the
ETS transcription factor family is placed under control of the
strongly androgen-responsive TMPRSS2 5 regulatory region
(27, 32).
At the same concentration, polyamide 1 and bicalutamide af-
fected a comparable number of transcripts, whereas polyamide 2
affected significantly fewer. When using bicalutamide as a point of
reference, the overall effects on genomic transcription by 1 and 2
are relatively modest. Although it is difficult to compare across
experimental conditions, the observation that a limited number of
genes are affected by each polyamide in this study is consistent with
previous reports (21). A comparison of the expression data for cells
treated with polyamide 1 or 2 reveal that some transcripts are
similarly affected, but many are differentially affected by the two
polyamides (Fig. 4A), which is consistent with previous compari-
sons of gene expression profiles of cells treated with polyamides of
different target sequence (21, 33).
The AR, glucocorticoid receptor, and estrogen receptor share
a highly conserved DNA-binding domain (34–36). This domain,
related to the classical Cys-2-His-2 zinc finger motifs (37),
contains two modules of zinc coordinated by four cysteines.
Previously, a polyamide targeted to the estrogen receptor re-
sponse element inhibited binding of estrogen receptors  and 
in gel-shift assays (38). In separate in vitro experiments, minor
groove-binding polyamides have been shown to inhibit the major
Table 1. Number of transcripts affected relative to DHT-induced controls (P < 0.01)
Treatment DHT
Up-regulated
(fold change  2.0)
Down-regulated
(fold change  2.0)
Up-regulated
(fold change  4.0)
Down-regulated
(fold change  4.0)
— — 486 782 88 199
B 	 611 602 96 133
1 	 347 706 42 126
2 	 95 284 11 32
—, No treatment.
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Fig. 4. Global effects on transcripts interrogated by using Affymetrix high-
density Human Genome U133 Plus 2.0 arrays. (A) Divisive clustering of all
measured transcripts under the four specified conditions: no treatment con-
trol, bicalutamide (B, 10 M), 1 (10 M), and 2 (10 M). Clustering was based
on an error-weighted Pearson correlation of intensity ratios for each treat-
ment as comparedwith DHT-induced controls. (B) Ven diagrams representing
transcripts down- and up-regulated (fold change  2.0, P  0.01) by bicalu-
tamide and 1. Numbers inside the intersections represent transcripts affected
by both treatments. Of the 122 transcripts down-regulated by both bicaluta-
mide and 1, 117 are also observed to be induced by DHT at the same thresh-
olds. (C) Agglomerative clusteringof expression changes of the 199 transcripts
induced or repressed 4-fold (P  0.01) or more by 1 nM DHT under the
designated treatment conditions. Of the DHT-induced set, 70 were inhibited
by polyamide 1, 20 were inhibited by 2, and 186 were inhibited by bicaluta-
mide (fold change  2.0, P  0.01). Clustering parameters were the same as
in A. Treatments reported are an error-weighted average from three exper-
iments, except the noninduced control, which was an average from two
experiments.
Table 2. Fold-changes of selected AR-target genes relative
to DHT-induced controls
Treatment DHT KLK2 KLK3 (PSA) TMPRSS2 FKBP5
— — 23.0 6.1 6.2 42.9
B 	 14.7 3.2 4.1 36.4
1 	 2.4 3.3 2.3 3.1
2 	 1.1 1.4 1.4 1.5
—, No treatment.
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groove binding of Zif268 and other zinc finger proteins to their
target sites on DNA by an allosteric mechanism (39). In light of
this observation, it is not unexpected that a polyamide targeted
to the ARE would inhibit AR binding.
The ARE is sufficiently degenerate such that a single poly-
amide is not likely to affect all AR-regulated genes simulta-
neously. The identities of the particular AR target genes involved
in prostate cancer progression are not fully known. In the
absence of this knowledge, it was our goal to target the ARE
broadly to maximize the number of AR target genes affected by
using a single polyamide. However, the programmability of
polyamides might allow selective inhibition of a predetermined
subset of AR target genes by one or a small mixture of tailored
polyamide molecules. The utility of disrupting the AR–ARE
interface with DNA-binding small molecules will depend on
continued experimentation in small animal models of hormone
refractory prostate cancer and AR-regulated gene expression
(40–42).
Materials and Methods
Synthesis of Polyamides. Polyamides 1 and 2 were synthesized by
solid-phase methods on Kaiser oxime resin (Nova Biochem,
Darmstadt, Germany) according to established protocols (43).
Polyamides were cleaved from resin with 3,3-diamino-N-
methyl-dipropylamine and purified by reverse-phase HPLC.
Isophthalic acid was activated with PyBOP (Nova Biochem) and
conjugated to the polyamides as described (22). Purities and
identities of the polyamides were assessed by HPLC, UV-visible
spectroscopy, and MALDI-TOF MS.
Determination of DNA-Binding Affinity and Sequence Specificity.
Plasmid pAR-PSA was constructed by inserting a 70-bp se-
quence from the PSA promoter containing the ARE into pUC19
plasmid. Quantitative DNase I footprint titration experiments
were used to measure the binding affinities of 1 and 2 on a
5-32P-labeled fragment of pAR-PSA that contains the PSA
promoter ARE. Detailed experimental protocols are reported
elsewhere (44).
Electrophoretic Mobility Shift Assay. The oligonucleotide 5-
GCATTGCAGAACAGCAAGTGCTAGCTCTCCC-3 con-
taining the PSA promoter ARE (underlined) was end-labeled
with 32P and annealed to its complement. Polyamides 1 and 2
were incubated with the duplex for 3 h in previously optimized
buffer conditions (45). Nuclear extract from DHT-treated LN-
CaP cells (Genetex, San Antonio, TX) was then added for an
additional 45 min. Complexes were run on a 5% polyacrylamide
gel and visualized on a phosphorimager.
Measurement of Androgen-Induced PSA mRNA and Protein. LNCaP
cells (ATCC) were plated in 24-well plates at a density of
40–50 103 cells per well (80–100 103 cells per ml) in RPMI
medium 1640 (ATCC) supplemented with 10% FBS (Irvine
Scientific, Santa Ana, CA). After 72 h, the medium was
replaced with RPMI medium 1640 containing 10% charcoal
stripped FBS with or without polyamides at the designated
concentrations. Cells were grown for an additional 48 h and
then treated with 1 nM DHT for 16 h. When appropriate,
bicalutamide was added 2 h before DHT stimulation. Isolation
of RNA and cDNA synthesis was performed as described (21).
Quantitative real-time RT-PCR was performed with SYBR
Green PCRMaster Mix (Applied Biosystems, Foster City, CA)
on an ABI 7300 instrument. PSA mRNA was measured
relative to -glucuronidase as an endogenous control. Primer
sequences are available upon request. Cell-culture superna-
tants were collected for an ELISA (R & D Systems, Minne-
apolis, MN) to measure PSA protein according to the manu-
facturer’s protocol.
Chromatin Immunoprecipitation. LNCaP cells were plated in 15-cm
diameter plates at a density of 2  106 cells per plate. Media,
polyamide treatment, time course, and DHT stimulation were
the same as described above. After the 16-h DHT treatment,
cells were treated with 1% formaldehyde for 10 min. Chromatin
was isolated and sheared. Antibodies to AR (AR-20, Santa Cruz
Biotechnology, Santa Cruz, CA) were used to immunoprecipi-
tate AR-bound DNA fragments. Crosslinks were reversed, and
PCRs using primers targeted to the regions of interest were used
to assess enrichment of bound fragments as compared with
mock-precipitated (no antibody) controls. PCRs weremonitored
with SYBR Green PCRMaster Mix (Applied Biosystems) on an
ABI 7300 instrument. Primer sequences and a more detailed
experimental protocol are available upon request.
Analysis of Gene Expression with Oligonucleotide Microarrays. LN-
CaP cells were plated in 12-well plates at a density of 80–100 
103 cells per well. Media, polyamide treatments, and time courses
were the same as described above. Bicalutamide was added 2 h
before DHT stimulation. RNA was isolated as described in ref.
21. From this point, experiments were carried out at the Millard
and Muriel Jacobs Gene Expression Facility at the California
Institute of Technology. Labeled mRNA was hybridized to
Affymetrix high-density Human Genome U133 Plus 2.0 arrays
according to established protocols. Gene expression was ana-
lyzed by using Resolver (Rosetta Biosoftware, Seattle, WA).
Data were uploaded to the Gene Expression Omnibus reposi-
tory (accession no. GSE7708).
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